Atea Pharmaceuticals (AVIR) Cash & Equivalents (2019 - 2026)

Atea Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $79.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 33.57% year-over-year to $79.3 million in Q1 2026; TTM through Mar 2026 was $79.3 million, a 33.57% decrease from a year earlier, with the FY2025 full-year figure at $95.7 million, down 78.78% from the prior year.
• Cash & Equivalents declined to $79.3 million in Q1 2026 per AVIR's latest filing, from $95.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $705.5 million in Q1 2022 and bottomed at $77.3 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $183.3 million (2023), against an average of $279.9 million.
• Across the five-year window, Cash & Equivalents sank 78.99% in 2022 and surged 213.59% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $188.5 million in 2022, then fell by 23.69% to $143.8 million in 2023, then jumped by 213.59% to $451.0 million in 2024, then plunged by 78.78% to $95.7 million in 2025, then retreated by 17.13% to $79.3 million in 2026.
• Per Business Quant, the three latest AVIR Cash & Equivalents figures stand at $79.3 million (Q1 2026), $95.7 million (Q4 2025), and $77.3 million (Q3 2025).